Clinical Trial Update: Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on the use of 6% hydroxyethyl starch (130/0.4) in cardiac surgical patients with postoperative kidney injury; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Surgery Complications
• Postoperative Kidney Injury

Drugs mentioned

• Hydroxyethyl starch 6% 130/0.4 (hydroxyethyl starch 6% 130/0.4)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Postoperative Kidney Injury | Phase 3 | Status: COMPLETED | Results posted: 2023-02-14